Advanced search
Publication Cover
Infection and Drug Resistance Volume 13, 2020 - Issue
Submit an article Journal homepage
298
Views
9
CrossRef citations to date
0
Altmetric
Original Research

In vitro Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam Against Carbapenem-resistant Enterobacteriaceae Isolates Collected from Three Secondary Hospitals in Southwest China Between 2018 and 2019

Chunhong Zou1 Department of Laboratory Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People’s Republic of China;2 College of Laboratory Medicine, Chongqing Medical University, Chongqing, People’s Republic of China
,
Jie Wei3 Department of Laboratory Medicine, West China Second University Hospital, Key Laboratory of Obstetric & Gynecologic and Pediatric Diseases and Birth Defects of Ministry of Education, Sichuan University, Chengdu, People’s Republic of China
,
Baoju Shan4 Pediatric Research Institute; Ministry of Education Key Laboratory of Child Development and Disorders; National Clinical Research Center for Child Health and Disorders (Chongqing), China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Children’s Hospital of Chongqing Medical University, Chongqing, People’s Republic of China;5 Chongqing Key Laboratory of Pediatrics, Children’s Hospital of Chongqing Medical University, Chongqing, People’s Republic of China
,
Xian Chen6 Department of Clinical Laboratory, The Affiliated Hospital of Qingdao University, Qingdao, People’s Republic of China
,
Deqiang Wang2 College of Laboratory Medicine, Chongqing Medical University, Chongqing, People’s Republic of China;7 The Key Laboratory of Molecular Biology of Infectious Diseases Designated by the Chinese Ministry of Education, Chongqing Medical University, Chongqing, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-5440-0427
ORCID Icon &
Siqiang Niu1 Department of Laboratory Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People’s Republic of ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-8911-7138
ORCID Icon
Pages 3563-3568 | Published online: 12 Oct 2020

References

  • Righi E, Peri AM, Harris PN, et al. Global prevalence of carbapenem resistance in neutropenic patients and association with mortality and carbapenem use: systematic review and meta-analysis. J Antimicrob Chemother. 2017;72(3):668–677. doi:10.1093/jac/dkw45927999023
  • Jee Y, Carlson J, Rafai E, et al. Antimicrobial resistance: a threat to global health. Lancet Infect Dis. 2018;18:939–940. doi:10.1016/S1473-3099(18)30471-730152350
  • WHO. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. Available from: https://www.who.int/medicines/publications/global-priority-list-antibiotic-resistant-bacteria/en/. Accessed 97, 2020.
  • CDC. Antibiotic Resistance Threats in the United States, 2019. https://www.cdc.gov/drugresistance/biggest-threats.html. Available from: Accessed 97, 2020.
  • Bush K. Past and present perspectives on β-lactamases. Antimicrob Agents Chemother. 2018;62:e01076–18. doi:10.1128/AAC.01076-1830061284
  • Lee CR, Lee JH, Park KS, et al. Global dissemination of carbapenemase-producing Klebsiella pneumoniae: epidemiology, genetic context, treatment options, and detection methods. Front Microbiol. 2016;7:895. doi:10.3389/fmicb.2016.0089527379038
  • Sader HS, Castanheira M, Shortridge D, Mendes RE, Flamm RK. Antimicrobial activity of ceftazidime–avibactam tested against multidrug-resistant Enterobacteriaceae and Pseudomonas aeruginosa isolates from U.S. medical centers, 2013 to 2016. Antimicrob Agents Chemother. 2017;61:e01045–17. doi:10.1128/AAC.01045-1728827415
  • Sader HS, Mendes RE, Pfaller MA, Shortridge D, Flamm RK, Castanheira M. Antimicrobial activities of aztreonam-avibactam and comparator agents against contemporary (2016) clinical Enterobacteriaceae isolates. Antimicrob Agents Chemother. 2018;62:e01856–17. doi:10.1128/AAC.01856-1729061754
  • Abboud MI, Damblon C, Brem J, et al. Interaction of avibactam with class B metallo-β-lactamases. Antimicrob Agents Chemother. 2016;60:5655–5662. doi:10.1128/AAC.00897-1627401561
  • Bush K. Game changers: new β-lactamase inhibitor combinations targeting antibiotic resistance in Gram-negative bacteria. ACS Infect Dis. 2018;4:84–87. doi:10.1021/acsinfecdis.7b0024329232103
  • Allergan, Inc. AVYCAZVR Package Insert. 2018 Available from: https://www.allergan.com/assets/pdf/avycaz_pi. Accessed 97, 2020.
  • Pfizer Pharmaceuticals. Zavicefta Summary of Product Characteristics. Available from: https://www.pfizer.com/news/press-release/press-release-detail/pivotal_phase_iii_study_underscores_efficacy_of_zavicefta_ceftazidime_avibactam_for_treatment_of_hospital_acquired_pneumonia_a_leading_cause_of_mortality_in_hospitals.. Accessed 9 26, 2020.
  • de Jonge BL, Karlowsky JA, Kazmierczak KM, et al. In vitro susceptibility to ceftazidime-avibactam of carbapenem-nonsusceptible Enterobacteriaceae isolates collected during the INFORM global surveillance study (2012 to 2014). Antimicrob Agents Chemother. 2016;60:3163–3169. doi:10.1128/AAC.03042-1526926648
  • Barnes MD, Winkler ML, Taracila MA, et al. Klebsiella pneumoniae carbapenemase-2 (KPC-2), substitutions at Ambler position Asp179, and resistance to ceftazidime–avibactam: unique antibiotic-resistant phenotypes emerge from β-lactamase protein engineering. mBio. 2017;8:e00528–17. doi:10.1128/mBio.00528-1729089425
  • Castanheira M, Mendes RE, Jones RN, et al. Changes in the frequencies of β-lactamase genes among Enterobacteriaceae isolates in U.S. hospitals, 2012 to 2014: activity of ceftazidime-avibactam tested against β-lactamase-producing isolates. Antimicrob Agents Chemother. 2016;60:4770–4777. doi:10.1128/AAC.00540-1627216075
  • Das S, Li J, Riccobene T, et al. Dose selection and validation for ceftazidime-avibactam in adults with complicated intra-abdominal infections, complicated urinary tract infections, and nosocomial pneumonia. Antimicrob Agents Chemother. 2019:63. doi:10.1128/AAC.02187-18.
  • Li H, Estabrook M, Jacoby GA, Nichols WW, Testa RT, Bush K. In vitro susceptibility of characterized beta-lactamase-producing strains tested with avibactam combinations. Antimicrob Agents Chemother. 2015;59:1789–1793. doi:10.1128/AAC.04191-1425534728
  • Wang Q, Wang X, Wang J, et al. Phenotypic and genotypic characterization of carbapenem-resistant Enterobacteriaceae: data from a longitudinal large-scale CRE study in China (2012–2016). Clin Infect Dis. 2018;67(Suppl2):S196–205. doi:10.1093/cid/ciy66030423057
  • Zhou T, Zhang X, Guo M, et al. Phenotypic and molecular characteristics of carbapenem-non-susceptible Enterobacteriaceae from a teaching hospital in Wenzhou, southern China. Jpn J Infect Dis. 2013;66:96–102. doi:10.7883/yoken.66.9623514904
  • Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. 29th ed. CLSI supplement M100 Wayne, PA: CLSI; 2019.
  • Iovleva A, Doi Y. Carbapenem-Resistant Enterobacteriaceae. Clin Lab Med. 2017;37(2):303–315. doi:10.1016/j.cll.2017.01.00528457352
  • Zou H, Xiong SJ, Lin QX, Wu ML, Niu SQ, Huang SF. CP-CRE/non-CP-CRE stratification and CRE resistance mechanism determination help in better managing cre bacteremia using CAZ/AVI and ATM/AVI. Infect Drug Resist. 2019;12:3017–3027. doi:10.2147/IDR.S21963531576152
  • Wei J, Zou C, Wang D, Huang A, Niu S. Genetic diversity and in vitro activity of ceftazidime/avibactam and aztreonam/avibactam against imipenem-resistant Enterobacteriaceae isolates in Southwest China: a single-centre study. J Glob Antimicrob Resist. 2020;2:448–451. doi:10.1016/j.jgar.2020.04.023

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.